Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim
{{output}}
Background: Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory appr... ...
